Jeena Sikho
Health | Wealth | Happiness

Date: 20th August, 2026

To,	To,
Manager - Listing Compliance **National Stock Exchange of India Limited** 'Exchange Plaza'. C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 SYMBOL: JSLL	Head of the Department, Department of Listing Operation, **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001 SCRIP Code: 544476

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that **Jeena Sikho Lifecare Limited** ("the Company") is issuing a press release titled **"JSLL Shares Update on IPD Growth and Business Mix."**

The Press Release provides an update on the Company's IPD growth, business mix and operating performance for the quarter ended June 30, 2026 (Q1 FY27).

Also, this information will be uploaded on the website of the Company at www.jeenasikho.com

A copy of the said Press Release is enclosed herewith for your information and records.

Kindly take the above intimation on record.

Thanking you,
Yours faithfully,

For Jeena Sikho Lifecare Limited

MANISH GROVER
Digitally signed by MANISH GROVER
Date: 2026.08.20 17:22:14 +05'30'

Manish Grover
Managing Director
DIN: 07557886

Place: Zirakpur, Punjab
Date: 20.08.2026

JEENA SIKHO LIFECARE LIMITED

Integrated Ayurveda & Wellness Healthcare

JSLL Shares Update on IPD Growth and Business Mix

New Delhi, August 20, 2026 - Jeena Sikho Lifecare Limited ("JSLL" or "the Company"), one of India's leading integrated Ayurveda healthcare providers, had announced its financial results for the quarter on 7th August, 2026, ended June 30, 2026 (Q1 FY27). The Company delivered revenue from operations of ₹224.4 crore, a growth of 29% over ₹174.3 crore in Q1 FY26. Growth was led by private-pay Panchakarma hospitalisation, at-centre medicine sales and the rapidly scaling digital/e-commerce medicine channel. Beyond the headline the company opens up on the mix shift that explains the revenue gap and their strategic focus to transition towards higher quality earnings.

Evolving towards a higher quality IPD mix – from panel heavy to private pay led

The Company's revenue is diversified across in-hospital Panchakarma services, at-centre and retail medicine, and digital channels. The table below presents Q1 FY27 revenue and the corresponding operating volume by channel, with private-pay and government-panel inpatient activity shown separately:

Channel	Revenue (₹ Cr)	YoY	Volume (Q1 FY27)	Vol. YoY
IPD – Panchakarma (private-pay)	84.8	+26%	11,500 admissions	+33%
OPD – Medicine (at-centre)	78.9	+18%	1.51 lakh footfall	+22%
E-commerce – Medicine(COD)	40.5	+1.9x	2.82 lakh orders	+3.9x
Day-care – Panchakarma	10.0	+46%	19,419 sessions	+31%
IPD -Panchakarma (Govt Panel)	5.2	-67%	975 patients	-52%
Consultation (OPD & tele)	4.5	+10%	69,119 consults	+65%
Diagnostics	1.3	New	-	-
Total revenue*	**224.4**	+29%	-	-

**Total is inclusive of net loyalty/other adjustments. Volumes represent admissions, footfall, sessions, orders or consultations as applicable. The 33% IPD growth referred to above represents private-pay admissions.*

Healthcare services revenue increased 13% YoY to ₹106.0 crore. Any "blended" IPD or Services number the Company reported in that period was, by construction, a mix of two structurally different businesses:

- Private-pay IPD - direct patient billing, collected on discharge.
- Government Panel - scheme-billed, but flagged by management as carrying slow collections - i.e., weaker cash conversion than the headline realisation implies.

In the table: Private-pay IPD revenue grew 26% YoY to ₹84.8 crore, with admissions growing a robust 33% YoY. The Company continues to focus on optimising centre economics as the network scales, with ARPOB and average length of stay being evaluated as key operating metrics for future disclosure. The services growth rate was moderated by lower government-panel revenue, which declined from ₹15.5 crore to ₹5.2 crore (share of total revenue from 8.9% → 2.3% while share of total services revenue: 16.5% → 4.9%)

Closing the growth-quality gap: Better mix. Better cash conversion. Boosting earnings quality.

The market-facing "+33% IPD volume" figure is private-pay admissions only (8,616 → 11,500). Set against Services revenue growth of just 13.2% (₹93.65 Cr → ₹106.02 Cr), which is explainable and is not a demand problem:

- **Leg 1 - price/mix within private-pay:** The Company is focusing on optimising patient mix and centre economics as volumes scale.
- **Leg 2 - Government Panel drag:** The Government Panel collapse (−₹10.3 Cr) offsets the services revenue gain, pulling reported Services growth down from +26% (private-IPD alone) to +13.2% (blended Services).
- **The blended reality:** On a blended basis (private + Government Panel, including day-care and excluding diagnostics/consultation), total IPD volume grew 16.9% and total IPD revenue grew 8.8%.

Commenting on the performance, Acharya Manish Grover, Managing Director and Chairman said: *"Q1 FY27 reflects continued scale-up across our integrated healthcare and medicines platform. Private-pay IPD admissions increased 33%, while our e-commerce medicine channel expanded sharply as we continued to build access across physical and digital formats. Healthcare services growth was moderated by our lower government-panel mix, consistent with our strategy of remaining predominantly private-pay. As the network expands, our focus remains on disciplined centre economics, quality of patient outcomes and sustainable profitable growth."*